Treatments | Variables (molecular subtypes, biomarker, genetic variation) | Â | Â | ||
---|---|---|---|---|---|
 | Molecular subtypes | OR | 95%CI | Overall P-value | Favoured outcome |
Taxane-Anthracycline | Luminal-like vs HER2E | 4.08 | 2.78,6.00 | P< 0.00001 | HER2E |
Luminal A vs HER2E | 5.27 | 1.16, 23.86 | P=0.03 | HER2E | |
Luminal B vs HER2E | 2.78 | 1.42,5.44 | P=0.0003 | HER2E | |
Luminal, combined vs HER2E | 3.89 | 2.69,5.64 | P< 0.00001 | HER2E | |
TNBC vs Luminal-like | 4.45 | 2.79,7.11 | P< 0.0001 | TNBC | |
TNBC vs Luminal A | 11.66 | 3.64, 37.38 | P< 0.00001 | TNBC | |
TNBC vs Luminal B | 3.89 | 2.20, 6.87 | P< 0.00001 | TNBC | |
TNBC vs Luminal, combined | 4.59 | 3.35, 6.29 | P< 0.00001 | TNBC | |
Taxane-platinum | Luminal-like vs HER2E (the subgroup-assessed outcome) | 2.30 | 1.66,319 | P< 0.00001 | HER2E |
Luminal A vs HER2E | 12.11 | 4.41,33.26 | P< 0.00001 | HER2E | |
Luminal B vs HER2E | 5.92 | 2.59,13.54 | P< 0.0001 | HER2E | |
Luminal, combined vs HER2E | 3.37 | 1.66, 6.84 | P= 0.0008 | HER2E | |
Luminal, combined vs HER2E (subgroup- assessed outcome) | 3.80 | 2.02,7.13 | P< 0.0001 | HER2E | |
Luminal B vs Luminal A | 3.26 | 1.14, 9.26 | P=0.03 | Luminal B | |
TNBC vs Luminal A | 7.14 | 2.82,18.04 | P< 0.0001 | TNBC | |
TNBC vs Luminal B | 2.19 | 1.09,4.41 | P=0.03 | TNBC | |
TNBC vs Luminal-like | 3.79 | 1.94, 7.40 | P< 0.0001 | TNBC | |
Anthracycline-based | Biomarkers | Â | Â | Â | Â |
ER− vs ER+ | 1.95 | 0.98,3.89 | P=0.06 | ER− | |
ER− vs ER+ (subgroup-population) | 2.52 | 1.43, 4.44 | P=0.001 | ER− | |
PR− vs PR+ | 2.40 | 1.52, 3.80 | P=0.0002 | PR− | |
HER2− vs HER2+ | 2.31 | 1.42,3.75 | P=0.0008 | HER2− | |
Taxane-based | HR− vs HR+ | 1.96 | 1.24, 3.08 | P=0.004 | HR− |
Taxane-anthracycline | ER− vs ER+ | 3.19 | 2.15, 4.75 | P< 0.00001 | ER− |
PR− vs PR+ | 3.11 | 2.12, 4.56 | P< 0.00001 | PR− | |
HR− vs HR+ | 2.38 | 0.87,6.53 | P=0.09 | HR− | |
HR− vs HR+ (Subgroup-population) | 3.58 | 1.62,7.90 | P=0.002 | HR− | |
HER2− vs HER2+ | 1.78 | 1.05,3.02 | P=0.0008 | HER2+ | |
nm23-H1− vs nm23-H1+ | 6.74 | 2.13,21.30 | P=0.001 | nm23-H1− | |
CK5/6− vs CK5/6+ | 1.87 | 1.03,3.39 | P=0.04 | CK5/6− | |
High Ki67 vs low Ki67 | 2.98 | 1.79,4.97 | P< 0.0001 | high Ki67 | |
High Ki67 vs low Ki67 (subgroup- 14% cut-off) | 1.82 | 0.65,5.10 | P=0.20 | high Ki67 | |
High Ki67 vs low Ki67 (subgroup- 14% cut-off, primary objective) | 3.12 | 1.93,5.04 | P< 0.00001 | high Ki67 | |
High Ki67 vs low Ki67 (Subgroup- 20% cut-off) | 2.88 | 1.36,6.10 | P=0.006 | high Ki67 | |
Taxane-platinum | ER− vs ER+ | 4.91 | 3.20,7.53 | P< 0.00001 | ER− |
PR− vs PR+ | 3.82 | 2.45,5.90 | P< 0.00001 | PR− | |
HR− vs HR+ | 2.71 | 1.43,5.41 | P< 0.00001 | HR− | |
High Ki67 vs low Ki67 | 2.20 | 0.74,6.59 | P=0.16 | high Ki67 | |
High Ki67 vs low Ki67 (Subgroup- 20% cut-off) | 4.37 | 1.62,11.75 | P=0.003 | high Ki67 | |
HER2− vs HER2+ | 2.44 | 0.84,7.06 | P< 0.0001 | HER2+ | |
HER2− vs HER2+ (Subgroup-influential) | 4.14 | 2.51,6.85 | P< 0.00001 | HER2+ | |
TP vs TA | In HER2+ breast cancer | 1.60 | 0.66,3.88 | P=0.30 | TP |
Subgroup- HER2+ breast cancer study | 2.36 | 1.07,5.26 | P=0.03 | TP | |
Taxane-anthracycline | Genetic variation | Â | Â | Â | Â |
PIK3CA wildtype vs PIK3CA mutated | 2.44 | 1.42,4.19 | P=0.001 | PIK3CA wildtype |